Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market – Forecasts from 2016 to 2021
DESCRIPTION Idiopathic pulmonary fibrosis (IPF) is an irreversible lung disease, in which the cells in the lung tissue surrounding the air sacs begin to die, as a result of which oxygen entering the bloodstream reduces, causing functional damage. Risk factors for the disease include smoking, exposure to certain types of dust, viral infection, gastroesophageal reflux disease and environmental concerns such as pollution. Since the disease is fatal, a lung transplant is a sought after treatment option while certain anti-inflammatory drugs and immunosuppressants slow down the impairment process. Factors driving the growth of the IPF diagnostic and treatment market are rising healthcare expenditure, growth in ageing population, burgeoning number of smokers and a healthy product pipeline for IPF therapy. Geographically the United States is expected to be the largest market for Idiopathic pulmonary fibrosis followed by Europe. Research Methodology This section provides an anatomy of the research process followed for calculating market size and forecasts along with a list of the secondary data sources used and the primary inputs which were taken for data validation. It also provides an outline of the various segmentations which have been covered as part of the report. Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Industry Overview In this section, the entire Idiopathic Pulmonary Fibrosis market is explained along with the causes, diagnosis, and prevention of the disease, the various drivers, restraints and opportunities to the market and the prevalence of the disease based on age, gender and region. A product pipeline of various drugs and vaccines for IPF therapy have been mentioned along with innovations in the market. Certain regulations specific to the industry are also listed out, followed by a detailed scenario analysis. Segmentation  By Type o Diagnostic Testing o Pharmacological Drugs Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market – Forecasts from 2016 to 2021
o Surgical Treatment By Geography o Americas North America South America o Europe Middle East and Africa Europe Middle East and Africa o Asia Pacific Market Players This Section deals with major players in the market, their market shares, products, growth strategies, financials, and recent investments among others. Key industry players in the Idiopathic pulmonary fibrosis treatment market are Roche, Boehringer Ingelheim, AdAlta and Aeolus Pharmaceuticals among others.
Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market – Forecasts from 2016 to 2021
TABLE OF CONTENTS 1. Introduction 2. Research Methodology 3. Executive Summary 4. Idiopathic Pulmonary Fibrosis Industry Overview 4.1. Market Overview 4.2. Drivers, Restraints, and Opportunities 4.3. Industry Value Chain Analysis 4.4. Prevalence 4.4.1. By Age Group 4.4.2. By Gender 4.4.3. By Region 4.5. Product Pipeline 4.6. Innovations 4.7. Industry Regulations 4.8. Scenario Analysis 5. Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Forecast by Type (US$ million) 5.1. Diagnostic Testing 5.2. Pharmacological Drugs 5.3. Surgical Treatment 6. Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market Forecast by Geography (US$ million) 6.1. Americas 6.1.1. North America 6.1.2. South America 6.2. Europe Middle East and Africa 6.2.1. Europe 6.2.2. Middle East and Africa 6.3. Asia Pacific 7. Competitive Intelligence 7.1. Market Share Analysis Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market – Forecasts from 2016 to 2021
7.2. Investment Analysis 7.3. Recent Deals 7.4. Strategies of Key Players 8. Company Profiles 8.1. Roche Holding AG 8.2. Boehringer Ingelheim 8.3. AdAlta 8.4. Aeolus Pharmaceuticals 8.5. Biogen Idec Inc. 8.6. BIORION 8.7. FibroGen 8.8. Gilead Sciences
Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market – Forecasts from 2016 to 2021
TO ORDER OR REQUEST FOR A SAMPLE: Product: Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market – Forecasts from 2016 to 2021 Link:https://www.knowledge-sourcing.com/products/idiopathic-pulmonary-fibrosisdiagnostic-and-treatment-market-forecasts-from-2016-to-2021 SKU: KSI0615346 Price: US$3,600 – Single User License US$5,600 – Multi User License US$7,600 – Enterprise License Payment: To pay by Credit Card, please, click “Add to Cart” button on product page and proceed with the payment For wire transfer, write to us at sales@knowledge-sourcing.com
For any custom requirements or queries, please visit our website or call us: Website: www.knowledge-sourcing.com Phone: +1-866-714-4587
Idiopathic Pulmonary Fibrosis Diagnostic and Treatment Market – Forecasts from 2016 to 2021